Executive record

Andrew Guggenhime

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:andrew-guggenhimeVersion: public-0As of: 2026-09-30

Not yet claimed9 published Claims2 sources

Key Claims

Biography

Experienced biopharmaceutical executive who has held CFO and COO roles at multiple life sciences companies including Dermira, CardioDx, and Calistoga Pharmaceuticals.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2026 to end not publishedExecutive title: President and Chief Financial Officer · Organization not publishedPCVX DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. PCVX DEF 14A executive officers

    sec filing · Source published: Apr 23, 2026 · Retrieved: Apr 29, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: Apr 29, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: Apr 29, 2026
    • Executive company: Executive at Vaxcyte Inc · Claim reviewed: May 3, 2026
    • Executive title: Executive title: President and Chief Financial Officer · Claim reviewed: May 3, 2026
    • Other Company Role: Andrew Guggenhime is also linked to Caribou Biosciences, Inc. as Chairman. · Claim reviewed: Apr 29, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: Apr 29, 2026

  2. PCVX executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise reported in filings · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
    • Executive company: Executive at Vaxcyte Inc · Claim reviewed: May 3, 2026
    • Executive function: Finance Controls (CFO) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: President and Chief Financial Officer · Claim reviewed: May 3, 2026